

# Essentials of Pharmacology

## for Health Professions



**Bruce J. Colbert, MS, RRT**  
**Adam J. James, PharmD**  
**Elizabeth D. Katrancha, DNP, CCNS, RN, CNE**

**Essentials of Pharmacology for Health Professions, Tenth Edition**  
**Bruce J. Colbert, Adam J. James,**  
**Elizabeth D. Katrancha**

SVP, Product Management: Cheryl Costantini

VP, Product Management: Mark Santee

Portfolio Product Director: Laura Stewart

Portfolio Product Manager: Andrea Henderson

Product Assistant: Renee Bunszel

Learning Designer: Debra Myette-Flis

Course Lead: Ken McGrath

Content Project Manager: Dinesh Deivendiran

Manager, Product Marketing: Annie Gillingham

Content Acquisition Analyst: Erin McCullough

Production Service: MPS Limited

Designer: Felicia Bennett

Cover Image Source: michaeljung/  
Shutterstock.com; Gravity Images/The Image  
Bank/Getty Images; Paola Giannoni/E+/Getty  
Images; Iakov Filimonov/Shutterstock.com;  
U.P.S.D/Shutterstock.com; Dmytro Zinkevych/  
Shutterstock.com; Iryna Rahalskaya/  
Shutterstock.com; BearFotos/Shutterstock.com;  
Alex\_Traksel/Shutterstock.com; Tyler Olson/  
Shutterstock.com; iStock.com/iStock Signature

Copyright © 2026 Cengage Learning, Inc. ALL RIGHTS RESERVED.

WCN: 02-300

No part of this work covered by the copyright herein may be reproduced or distributed in any form or by any means, except as permitted by U.S. copyright law, without the prior written permission of the copyright owner.

Previous edition(s): © 2023, © 2019, © 2015

For product information and technology assistance, contact us at  
**Cengage Customer & Sales Support, 1-800-354-9706**  
**or support.cengage.com.**

For permission to use material from this text or product, submit all  
requests online at **www.copyright.com**.

Library of Congress Control Number: 2024926877

ISBN: 979-8-214-11606-8

**Cengage**  
5191 Natorp Boulevard  
Mason, OH 45040  
USA

Cengage is a leading provider of customized learning solutions. Our employees reside in nearly 40 different countries and serve digital learners in 165 countries around the world. Find your local representative at: **www.cengage.com**.

To learn more about Cengage platforms and services, register or access your online learning solution, or purchase materials for your course, visit  
**www.cengage.com**.



# Contents

List of Tables / vii

Dedication / ix

Preface / xi

## Part 1 Introduction to Pharmacologic Principles

### Chapter 1

### Consumer Safety and Drug Regulations 2

Drug History / 3

Pharmacology Timeline / 4

Drug Laws / 5

FDA and DEA / 10

Health Care Professionals and the Law and Ethics / 10

### Chapter 2

### Drug Names and References 15

Classifications / 16

Identifying Names / 17

Legal Terms Referring to Drugs / 20

Terms Indicating Drug Actions / 21

Drug References / 23

The Internet as Reference / 23

### Chapter 3

### Sources and Bodily Effects of Drugs 26

Sources of Drugs / 27

Effects of Drugs / 29

Drug Processing by the Body (Pharmacokinetics) / 29

Other Variables Affecting Drug Action / 33

Unexpected Responses to Drugs / 39

### Chapter 4

### Medication Preparations and Supplies 44

Drug Forms and Devices / 45

Supplies / 57

### Chapter 5

### Abbreviations and Systems of Measurement 63

Abbreviations / 63

Systems of Measurement / 69

### Chapter 6

### Safe Dosage Calculations 77

Calculation Guidelines / 82

Method 1: Basic Calculation / 83

Method 2: Ratio and Proportion / 86

Pediatric Dosage / 89

Geriatric Dosage / 91

Prevention of Medication Errors / 91

### Chapter 7

### Responsibilities and Principles of Drug Administration 97

Responsible Drug Administration / 97

Medication Errors / 99

Principles of Administration / 100

MedWatch / 104

## Chapter 8

### Administration by the Gastrointestinal Route 109

Administration of Medications Orally / 111

Administration of Medications Rectally / 116

Administration of Rectal Suppository / 117

Administration of Medications by Percutaneous Endoscopic

Gastrostomy (PEG) or Nasogastric Tube (NGT) / 118

## Chapter 9

### Administration by Parenteral and Other Routes 124

Sublingual and Buccal Administration / 125

Transcutaneous Drug Delivery System / 126

Inhalation Route / 128

Injections / 131

IV Medications / 145

Skin Medications / 146

Eye Medications / 146

Ear Medications / 148

## Chapter 10

### Poison Control 157

Poisoning by Ingestion / 158

Poisoning by Inhalation / 159

External Poisoning of Skin or Eyes / 160

Poisoning by Sting and Snakebite / 160

People at Risk / 161

## Part 2 Drug Classifications

### Chapter 11

### Nutritional Concepts of Pharmacology 168

Fat-Soluble Vitamins / 170

Water-Soluble Vitamins / 174

Minerals / 183

Antioxidants / 192

Alternative Medicines / 193

Suggested Readings / 200

Topical Immunomodulators / 220

Cautions for Topical Medications / 221

## Chapter 13

### Autonomic Nervous System Drugs 225

Adrenergics / 228

Adrenergic Blockers / 231

Cholinergics / 233

Cholinergic Blockers / 235

### Chapter 12

### Integumentary System Medications 203

Antipruritics / 204

Corticosteroids / 205

Emollients and Protectants / 206

Keratolytics / 207

Enzyme Preparations / 207

Scabicides and Pediculicides / 209

Local Anti-Infectives / 211

Burn Medications / 217

Agents Used to Treat Acne / 219

## Chapter 14

### Cardiovascular System Medications 240

Cardiac Glycosides (Digoxin) / 241

Antiarrhythmic Agents / 243

Antihypertensives / 250

Other Antihypertensives / 253

Coronary Vasodilators / 257

Antilipemic Agents / 260

Antithrombotic Agents / 266

Thrombolytic Agents / 272

Hematopoietic Agents / 273

**Chapter 15****Urinary System Drugs 279**

- Diuretics / 279
- Medications for Gout / 285
- Bladder Antispasmodics / 289
- Cholinergics / 291
- Urinary Analgesics / 292
- Treatment of Benign Prostatic Hyperplasia / 294

**Chapter 16****Gastrointestinal Drugs 300**

- Antacids / 301
- Agents for Treatment of Ulcers and Gerd / 302
- Gastric Mucosal Agents / 304
- GI Antispasmodics or Anticholinergics / 307
- Agents for Inflammatory Bowel Disease / 308
- Antidiarrheal Drugs / 310
- Antiflatulents / 313
- Laxatives and Cathartics / 315
- Antiemetics / 321

**Chapter 17****Respiratory System Drugs and Antihistamines 328**

- Respiratory Diseases and Disorders / 328
- Oxygen Therapy / 329
- Respiratory Stimulants / 329
- Bronchodilators / 330
- Corticosteroids / 336
- Asthma Prophylaxis / 338
- Mucolytics and Expectorants / 340
- Antitussives / 342
- Antihistamines / 344
- Decongestants / 347
- Safety of Cough–Cold–Allergy Products / 349
- Smoking-Cessation Aids / 350

**Chapter 18****Eye and Ear Medications 358**

- Anti-Infectives / 358
- Anti-inflammatory Agents / 360
- Antiglaucoma Agents / 363
- Mydriatics / 370
- Local Anesthetics / 371
- Otic (Ear) Medications / 372

**Chapter 19****Central Nervous System Drugs: Analgesics, Sedatives, and Hypnotics 378**

- Analgesics / 378
- Antimigraine Agents / 392
- Sedatives and Hypnotics / 395

**Chapter 20****Psychotropic Medications, Alcohol, Drug Abuse, and Withdrawal Treatment 403**

- CNS Stimulants / 404
- Selective Norepinephrine Reuptake Inhibitor (SNRI) for ADHD / 407
- Antidepressants / 409
- Antimanic Agents / 416
- Anxiolytics / 418
- Antipsychotic Medications/Major Tranquilizers / 422
- Substance Abuse / 429
- Alcohol / 429
- Alcohol Poisoning / 431
- Prescription Drug Abuse / 432
- Illegal Drug Abuse / 433

**Chapter 21****Musculoskeletal and Anti-Inflammatory Drugs 441**

- Skeletal Muscle Relaxants / 441
- Anti-Inflammatory Drugs / 444
- Osteoporosis Therapy / 449

**Chapter 22****Anticonvulsants, Antiparkinsonian Drugs, and Agents for Alzheimer's Disease 457**

- Anticonvulsants / 458
- Drug Therapy for Generalized and Partial Seizures / 460
- Drug Therapy for Febrile Seizures / 462
- Drug Therapy for Absence Seizures / 462
- Antiparkinsonian Drugs / 465
- Agents for Restless Legs Syndrome / 472
- Agents for Alzheimer's Disease / 472

## Chapter 23

### Endocrine System Drugs 478

- Pituitary Hormones / 479
- Adrenal Corticosteroids / 480
- Thyroid Disorders / 483
- Antidiabetic Agents / 488

## Chapter 24

### Reproductive System Drugs 507

- Gonadotropics / 507
- Androgens / 508
- Erectile Dysfunction Medications / 510
- Estrogens / 512
- Progestins / 515
- Choice of Contraceptives / 520
- Drugs for Labor and Delivery / 524
- Other Gonadotropic Drugs / 529

## Chapter 25

### Anti-Infective Drugs 534

- Resistance / 535
- Adverse Reactions / 536
- Immunizations / 537
- Monoclonal Antibody Vaccines / 538
- Antibiotics / 538
- Aminoglycosides / 540
- Cephalosporins / 541
- Macrolides / 542
- Penicillins / 544
- Carbapenems / 545
- Quinolones / 547
- Tetracyclines / 549
- Antifungals / 550

*Summary / 609*

*Comprehensive Exam for Part 1 / 611*

*Comprehensive Exam for Part 2 / 617*

*Glossary / 623*

*Index / 639*

- Antituberculosis Agents / 552
- Miscellaneous Anti-Infectives / 556
- Agents for VRE / 557
- Sulfonamides / 560
- Urinary Anti-Infectives / 561
- Antivirals / 562
- Treatment of Human Immunodeficiency Virus/AIDS Infections / 565

## Chapter 26

### Antineoplastic Drugs 573

- Antimetabolites / 576
- Alkylating Agents / 577
- Mitotic Inhibitors / 577
- Antitumor Antibiotics / 580
- Hormones and Hormone Modifiers / 580
- Biological Therapies / 581
- Colony-Stimulating Factors (CSFs) / 582
- Monoclonal Antibodies (MABs) / 582
- Targeted Therapies / 583
- Vaccines / 584
- Radioactive Isotopes / 585
- Cautions and Responsibilities for Antineoplastic Drugs / 585


## Chapter 27

### Age-Related Medication Issues 592

- Older Adult Considerations / 593
- Physiologic Changes with Increasing Age / 593
- Potentially Inappropriate Medication Use in Older Adults / 596
- Drugs to Avoid with Certain Medical Conditions / 596
- Polypharmacy / 599
- Issues with Adherence / 601
- Pediatric Considerations / 602

| Schedule Number    | Abuse Potential and Legal Limitations  | Examples of Substances  |
|--------------------|--|---|
| 4, C <sub>IV</sub> | <p>Lower abuse potential than the previous schedules</p> <p>Prescription may be written out by the health care professional but must be signed by the physician</p> <p>Prescription may be phoned in by the health care professional or faxed</p> <p>May be refilled up to five times in six months</p> <p>All C-IV prescriptions are uploaded to the state's (if available) prescription drug monitoring program (PDMP)</p> | Valium, Ativan, Xanax, phenobarbital, Librium, Restoril, Ambien |
| 5, C <sub>v</sub>  | <p>Low abuse potential compared to the previous schedules</p> <p>Consists primarily of preparations for cough suppressants containing codeine and preparations for diarrhea (e.g., diphenoxylate)</p> <p>May be refilled up to five times in six months</p>  | promethazine with codeine, Cheratussin AC, Lomotil              |

**Note:** This control schedule can vary from state to state. Some states may have stricter schedules than the federal regulations. You must be aware of the regulations in your area.



**Figure 1-3** Controlled substance schedule numbers appear in a variety of drug information resources, including (A) drug packages and (B) drug inserts. Schedule numbers are also found in drug reference sources.

## Clinical Application

Although many other drug laws exist, there are two significant pieces of drug legislation that are important to mention here. The 1983 Orphan Drug Act gives pharmaceutical companies financial incentives to develop medications for diseases that affect only a small number of people. This encourages the companies to develop **orphan drugs** that would otherwise be of low

profitability. The other legislation is the strangely named Omnibus Budget Reconciliation Act (OBRA) of 1990. This act mandates that all OTC drugs a patient is taking must be documented as part of the medical record. OBRA also mandates that pharmacists provide drug use review and patient counseling before dispensing prescriptions to a patient.

4. Shake the actuator off to remove as much water as possible and allow the actuator to dry overnight.
5. Replace the canister in the actuator and shake well, spray two sprays into the air away from your face, then replace the cap on the mouthpiece.

**Dry-powder inhalers (DPIs)** provide medication (especially corticosteroids and long-acting beta<sub>2</sub> agonists) only under the pressure of spontaneous inspiration rather than through compression of the valve (Figure 17-2). Therefore, the patient must be able to generate sufficient inspiratory effort on their own to deliver the medication, and therefore this device should not be used in acute respiratory distress. This option is helpful for patients who are unable to coordinate inspiration with actuation of a conventional MDI.

**Small-volume nebulizers (SVNs)**, more commonly referred to as nebulizers, create an aerosol mist of a drug solution that can then be inhaled into the lungs through a mouthpiece or a mask. The aerosol is created by either compressed air or oxygen gas, and the optimal breathing pattern is a slow, deep breath with a sustained breath hold; the aerosol should be delivered over an 8–12-min period (refer to Figure 17-3).



Orawan Pattarawimonchai/Shutterstock.com.

**Figure 17-2** An example of a dry-powder inhaler (DPI).



ChooChin/Shutterstock.com.

**Figure 17-3** Child receiving a small-volume nebulizer (SVN) aerosol treatment with a mask.

## Sympathomimetics

**Sympathomimetics** (adrenergics) are potent bronchodilators that increase vital capacity and decrease airway resistance. The adrenergics work on the smooth muscle in the lungs to cause relaxation. Examples include albuterol, epinephrine, and salmeterol.

An important classification system is differentiating between short-acting beta agonists (SABAs) and long-acting beta agonists (LABAs). SABAs, such as albuterol, are the drug of choice for managing acute exacerbations of asthma. LABAs, such as salmeterol, are used for prophylactic treatment. SABAs are also known as *rescue medications*, as opposed to the LABAs, which are known as **maintenance medications**.

**Side effects** of the adrenergics include potentiation of theophylline effects with increased risk of toxicity, especially:

Gastrointestinal (GI) (nausea, vomiting, and decreased appetite)

Cough, throat irritation, hoarseness, and sinusitis with inhaled preps

Drug classifications (*continued*)  
restless legs syndrome agents, 472  
sedatives and hypnotics, 398–399  
vitamins, minerals, and herbs, 167–199

Drug Enforcement Administration (DEA), 8, 10, 68

Drug errors, 19, 20

Drug forms  
defined, 44  
inhalable, 56  
injectable, 47–52, 49  
mucosal, 53  
oral, 45–47, 48  
rectal, 47  
and right medication, 100–102  
safety devices, 60  
standard, 45–56  
supplies, 56–60, 57–58  
topical, 52–54, 52, 53

Drug history, 3–4

Drug-induced parkinsonism (DIP), 466

Drug inserts, 6, 9

Drug interactions, 22, 34–35

Drug label, 21

Drug laws, 5–9  
Controlled Substances Act, 8  
FDA and DEA, 10  
Federal Food, Drug, and Cosmetic Act and  
Amendments of 1951 and 1962, 6  
health care practitioners and, 10–11  
Omnibus Budget Reconciliation Act, 9  
Orphan Drug Act, 9  
Pure Food and Drug Act, 5

Drug packages, 9

Drug preparation. *See* Drug forms

Drug processes, 29

Drugs  
administration routes, 36–39  
allergic reactions to, 19, 41  
dosage, 35  
effects of, 29  
errors, 19  
interactions, 34–35  
Internet as reference, 23–24  
legal terms referring to drugs, 20–21  
legend, 6

orphan, 9  
physiologic changes with age, 593–595  
processing by the body, 29–33  
reference sources for, 9, 23  
sources of, 27, 28  
terms indicating actions, 21–23  
unexpected responses to, 39–41

Drug standards, 5

Drug therapy  
for absence seizures, 462–464  
for febrile seizures, 462  
for generalized and partial seizures, 460–462

Dry-powder inhalers (DPIs), 56, 128, 331, 331

Duexis, 302

Dulaglutide, 499

Duloxetine, 391, 415

Duodenal ulcer, 304

Duragesic, 53, 126

Dutasteride, 296

Dyazide, 19

Dyrenium, 282

Dysphagia, 110

---

**E**

Ear drops, 53, 373

Ear medications, 148–149, 148  
ear wax building and blockage, 374, 374  
otitis media, 372  
systematic preparations for ear infections, 374  
topical preparations for ear infections,  
372–373

Echinacea, 197

Ecotrin, 274

Efavirenz, 566

Effient, 274

Eicosapentaenoic acid (EPA), 264

Eldepryl, 468

Electrolytes, 183

Electronic drug references, 23

Electronic medication administration record  
(eMAR), 23, 68, 69

Eletriptan, 394

Eliquis, 267

Elixir, fluid extract, 47

Emesis, 159, 321